Literature DB >> 16776777

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Kazu Shiomi1, Hideaki Miyamoto, Tatsuya Segawa, Yoshiaki Hagiwara, Akinobu Ota, Masahiro Maeda, Kazuhisa Takahashi, Kimihiko Masuda, Yukinori Sakao, Okio Hino.   

Abstract

We have developed a novel enzyme-linked immunosorbent assay (ELISA) system for the detection of N-ERC/mesothelin in the serum of mesothelioma patients and have begun to examine its clinical usefulness. N-ERC/mesothelin is a 31-kDa protein that forms the N-terminal fragment of the full-length 71-kDa ERC/mesothelin protein, and is physiologically secreted into the blood of mesothelioma patients where it can be detected using our sandwich ELISA containing two antibodies (rabbit polyclonal anti-ERC/mesothelin antibody-282 and mouse monoclonal antibody 7E7). Our ELISA system has thus far detected much higher serum levels of N-ERC/mesothelin in mesothelioma patients than in healthy controls or patients with other lung or pleural diseases. In conclusion, N-ERC/mesothelin is a promising candidate tumor marker for mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16776777     DOI: 10.1111/j.1349-7006.2006.00246.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  23 in total

Review 1.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  The continual search for ideal biomarkers for mesothelioma: the hurdles.

Authors:  Fraser J Brims; Y C Gary Lee; Jenette Creaney
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Diagnostic tumor marker of asbestos-related mesothelioma.

Authors:  Okio Hino; Masahiro Maeda
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

4.  Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma.

Authors:  Kohta Imashimizu; Kazu Shiomi; Masahiro Maeda; Naoko Aoki; Kiyoko Igarashi; Fumio Suzuki; Mitsuru Koizumi; Kenji Suzuki; Okio Hino
Journal:  Exp Ther Med       Date:  2011-03-08       Impact factor: 2.447

5.  The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.

Authors:  Takanori Mori; Ken Tajima; Michihiro Hirama; Tadashi Sato; Kenji Kido; Shin-Ichiro Iwakami; Shinichi Sasaki; Akihiko Iwase; Kazu Shiomi; Masahiro Maeda; Okio Hino; Kazuhisa Takahashi
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

Review 6.  Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors:  Mitchell Ho
Journal:  BioDrugs       Date:  2011-10-01       Impact factor: 5.807

Review 7.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.

Authors:  Harumi Saeki; Akane Hashizume; Hiroshi Izumi; Fujihiko Suzuki; Kazuhisa Ishi; Michio Nojima; Masahiro Maeda; Okio Hino
Journal:  Oncol Lett       Date:  2012-07-11       Impact factor: 2.967

Review 9.  Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.

Authors:  Hui Liu; Licun Wu; Kai Ji; Wei Wang
Journal:  Tumour Biol       Date:  2015-09-11

Review 10.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.